Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07206225 · ClinicalTrials.gov registry record · Phase 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

A Phase 1 study of Non-muscle Invasive Bladder Cancer, sponsored by Pfizer.

Recruiting
Registry status
Phase 1
Development phase
294
Enrollment target
20
Study locations

NCT07206225 is a Phase 1 study of Non-muscle Invasive Bladder Cancer that is actively recruiting participants, run by Pfizer. The registered enrollment target is 294 participants, above the 223-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (32% higher). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07206225, a Phase 1 study of Non-muscle Invasive Bladder Cancer, is actively recruiting participants, sponsored by Pfizer.

RECRUITING
Registry status
Phase 1
Development phase
294 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based on their doctor's opinion, cannot receive standard treatments or those treatments are not available to them. The study has three parts: * Part 1 (monotherapy dose escalation) will test PF-08052667 as a single-agent at increasing dose levels in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 2 (combination dose escalation) will test PF-08052667 in combination with BCG and/or sasanlimab (fixed dose) in participants with certain bladder cancer whose disease has worsened on or after standard treatments. * Part 3 (dose optimization and expansion) will further test PF-08052667 as a single agent or in combination with BCG and/or sasanlimab, at the dose(s) based on findings from Part 1 and Part 2 in participants with certain bladder cancer including those who has never received standard treatments. All participants will receive the study drug PF-08052667. Only participants in Part 2 and Part 3 of the study will also receive BCG and/or sasanlimab. PF-08052667 will be given as an intravesical infusion, which means it will be injected directly into the bladder. Sasanlimab will be given as a subcutaneous injection, which means it will be injected under the skin. For all parts, treatment with study medicines will continue until either a participant has decided to stop taking part in the study or is asked to leave the study for various reasons or up to about 2 years, whichever occurs first. Duration of trial

Conditions Studied

Non-muscle Invasive Bladder Cancer

Interventions

  • DRUG PF-08052667
  • DRUG Sasanlimab
  • DRUG BCG
  • DRUG PF-02921367

Study Locations (20)

Florida

  • AdventHealth Orlando - Orlando
  • Moffitt Cancer Center at SouthShore - Ruskin
  • Moffitt Cancer Center - International Plaza - Tampa
  • Moffitt Cancer Center - McKinley Campus - Tampa
  • Moffitt Cancer Center - Tampa
  • Moffitt McKinley Hospital - Tampa
  • Moffitt Cancer Center at Wesley Chapel - Wesley Chapel

Kansas

  • The University of Kansas - Clinical Research Center - Fairway
  • The University of Kansas Hospital Cambridge North Tower A - Kansas City
  • The University of Kansas Hospital - Kansas City
  • The University of Kansas Medical Center Medical Office Building - Kansas City
  • The University of Kansas Hospital - Indian Creek Campus - Overland Park

Georgia

  • Emory University Hospital Midtown - Atlanta
  • Emory University Hospital - Atlanta
  • Emory University - Atlanta

Illinois

  • Northwestern Memorial Hospital - Chicago
  • Northwestern University - Feinberg School of Medicine - Chicago

Alabama

  • University of Alabama at Birmingham - Birmingham

California

  • UCLA Hematology/Oncology - Westwood (Building 300) - Los Angeles

Iowa

  • University of Iowa Health Care - Iowa City

Trial Details

FieldValue
Enrollment Target 294 participants
Start Date 2025-11-06
Est. Completion 2033-01-28
Phase Phase 1

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07206225

The ClinicalTrials.gov registry entry for NCT07206225 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 294 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 223-participant average among 28 other Non-muscle Invasive Bladder Cancer trials with a reported enrollment target (32% higher). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Non-muscle Invasive Bladder Cancer appearing as the primary indexed condition, and to 4 interventions - of which PF-08052667 is the first listed.

NCT07206225 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Florida, Kansas, Georgia.

Frequently Asked Questions

What is clinical trial NCT07206225 about?

NCT07206225 is a clinical study titled "A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer". The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the ...

What is the current status of trial NCT07206225?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 294 participants. The study started on 2025-11-06. Estimated completion is 2033-01-28.

What conditions does trial NCT07206225 study?

This clinical trial studies the following conditions: Non-muscle Invasive Bladder Cancer.

What interventions are being tested in trial NCT07206225?

The interventions under investigation include: PF-08052667 (DRUG), Sasanlimab (DRUG), BCG (DRUG), PF-02921367 (DRUG).

Who is sponsoring clinical trial NCT07206225?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07206225 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-muscle Invasive Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-muscle Invasive Bladder Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.